• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dermata Therapeutics, Inc. - Warrant (NQ:DRMAW)

    0.0221 +0.0052 (+30.77%)
    Streaming Delayed Price Updated: 9:39 AM EDT, Sep 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Dermata Therapeutics, Inc. - Warrant

    < Previous 1 2 Next >
    Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
    Via ACCESS Newswire
    Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
    Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
    Via ACCESS Newswire
    Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    Via ACCESS Newswire
    Dermata to Present on BioPub on January 31, 2025
    Via ACCESS Newswire
    Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
    Via ACCESSWIRE
    Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
    Via ACCESSWIRE
    Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
    Via ACCESS Newswire
    Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    Via ACCESS Newswire
    Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
    Via ACCESS Newswire
    Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
    Via ACCESSWIRE
    Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
    Via ACCESSWIRE
    Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
    Via ACCESSWIRE
    Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
    Via ACCESS Newswire
    Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
    Via ACCESS Newswire
    Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    Via ACCESS Newswire
    Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
    Via ACCESS Newswire
    Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
    – Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
    Via ACCESSWIRE
    Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
    Via ACCESSWIRE
    Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    Via ACCESSWIRE
    Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    Via ACCESSWIRE
    Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
    Via ACCESSWIRE
    Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
    Via ACCESSWIRE
    Dermata to Present at the Emerging Growth Conference on April 3, 2024
    Via ACCESSWIRE
    Dermata to Present at the Emerging Growth Conference on February 7, 2024
    Via ACCESSWIRE
    Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
    Via ACCESSWIRE
    Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
    Via ACCESSWIRE
    Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
    Via ACCESSWIRE
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.